Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.